However, based on the growing knowledge of the molecular properties of Gal-3 and its complex mechanism of action, as well as advancing knowledge of the pathophysiology of HF and the therapeutic approach, there is a space for tailoring medical procedures depending on the characteristics of the patient population and the time point of the developing pathology. This evidence concerns the gene LGALS3 and hydrops fetalis.